MMSI — Merit Medical Systems, Inc.

Is MMSI overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Overbought As of August 19, 2026

Merit Medical Systems, Inc. (MMSI) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $89.26. The rating moved from Neutral to Overbought on July 17, 2026.

See all overbought Healthcare stocks →

AI analysis

Merit Medical Systems, Inc. presents a durable business model driven by recurring consumables and a diversified interventional device portfolio. Near-term catalysts include benefits from rising diagnostic/screening volumes and broader biologics/contract-manufacturing strength that support demand for procedural supplies. Financial resilience is helped by a mix of capital equipment and high-margin aftermarket sales, though exposure to hospital capital cycles, reimbursement pressure, supply-chain disruptions and regulatory risk are meaningful. Given current market tone favoring growth and the company’s market position, upside over the next month appears plausible if execution and procedure volumes remain steady; downside risk would be concentrated in a sharp pullback in elective procedures or material regulatory setbacks.

Key factors

  • Market-leading position in interventional devices and recurring consumables creates stable revenue base and high aftermarket attachment rates
  • Diversified product portfolio across vascular, endoscopy and other hospital consumables reduces single-market exposure
  • Sector tailwinds from expanded diagnostic/screening demand and increased biologics/CRO activity could drive durable consumables and device demand
  • Reasonable balance between capital equipment sales and high-margin consumables supports margin resilience during moderate demand fluctuations
  • Macro backdrop of mild risk-on investor sentiment and lower long-term yields supports M&A optionality and valuation expansion in healthcare equipment

Risks

  • Hospital capital spending and procedure volumes are cyclical; a slowdown in elective procedures would meaningfully reduce sales
  • Reimbursement pressure and payer-driven margin optimization could compress pricing over time for certain devices and services
  • Supply-chain disruption or input-cost inflation could erode margins if not passed through to customers
  • Regulatory or product-quality issues (recalls, FDA actions) could disrupt operations and harm reputation
  • Execution risk from international expansion, new product commercialization or integration of any acquisitions
  • Limited social and real-time sell-side commentary available to validate short-term sentiment; retail chatter is guarded

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MMSI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.